King Wealth United Therapeutics Corp Transaction History

King Wealth

$686 Million
Q4 2024

A detailed history of King Wealth transactions in United Therapeutics Corp stock. As of the latest transaction made, King Wealth holds 1,500 shares of UTHR stock, worth $536,250. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,500

Previous 1,500 -0.0%

Holding current value

$536,250

Previous $538,000 1.67%

% of portfolio

0.08%

Previous 0.08%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$311.04 - $363.55 $155,520 - $181,775	-500 Reduced 25.0%	1,500 $538,000
Q2 2024 Aug 08, 2024	SELL	$228.26 - $319.04 $684,780 - $957,120	-3,000 Reduced 60.0%	2,000 $637,000
Q3 2022 Nov 10, 2022	SELL	$203.3 - $244.17 $203,300 - $244,170	-1,000 Reduced 16.67%	5,000 $1.05 Million
Q2 2022 Aug 11, 2022	SELL	$174.81 - $241.14 $611,835 - $843,990	-3,500 Reduced 36.84%	6,000 $1.41 Million
Q1 2022 May 12, 2022	BUY	$166.16 - $213.96 $332,320 - $427,920	2,000 Added 26.67%	9,500 $1.7 Million
Q2 2021 Aug 12, 2021	SELL	$170.47 - $211.93 $85,235 - $105,965	-500 Reduced 6.25%	7,500 $1.35 Million
Q4 2020 Feb 12, 2021	SELL	$101.87 - $151.79 $101,870 - $151,790	-1,000 Reduced 11.11%	8,000 $1.21 Million
Q3 2020 Nov 12, 2020	BUY	$99.9 - $121.13 $99,900 - $121,130	1,000 Added 12.5%	9,000 $909,000
Q2 2020 Aug 13, 2020	BUY	$92.74 - $125.82 $463,700 - $629,100	5,000 Added 166.67%	8,000 $968,000
Q4 2019 Feb 13, 2020	BUY	$78.31 - $95.34 $234,930 - $286,020	3,000 New	3,000 $264,000

Others Institutions Holding UTHR

# of Institutions

723

Shares Held

60.9M

Call Options Held

123K

Put Options Held

104K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of King Wealth, based on Form 13F filings with the SEC.

News

Stay updated on King Wealth with notifications on news.

Account